AFFILIATIONS
1 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, China
2 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, ChengDu, China
3 Affiliated Hosptial of North Sichuan Medical College, NanChong, China
4 Guang yuan Central Hospital, Guang yuan, China
5 Chengdu Second People's Hospital, Chengdu, China
6 Chengdu Seventh People's Hospital, Chengdu, China
7 Chengdu Third People's Hospital, Chengdu, China
8 Deyang People's Hospital, ChengDu, China
9 Department of Hematology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China
10 Yibin Second People's Hospital, Yibin, China
11 Hematology department, Mianyang central hospital,School of Medicine.University of Electronic Science and Technology of China, Mianyang, China
12 The Affiliated Hospital of Southwest Medical University, Luzhou, China
13 Chengdu First People's Hospital, ChengDu, China
14 Chengdu Fifth People's Hospital, ChengDu, China
15 The Fourth People's Hospital of Zigong, Zigong, China
16 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, ChengDu, China
17 Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, ChengDu, China
18 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital,Sichuan University, ChengDu, China
19 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospita,Sichuan University, ChengDu, China
20 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China; National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University., ChengDu, China
ABSTRACT
Background
Peripheral T-cell lymphomas (PTCLs) are aggressive mature T-cell neoplasms with poor outcomes after CHOP. Golidocitinib, a highly selective JAK1 inhibitor, has shown antitumor activity in relapsed or refractory PTCL. Therefore, it is of interest to evaluate Golidocitinib in combination with CHOP as first-line treatment for patients with PTCL.
Methods
JACKPOT52 (ChiCTR2500107078) is an ongoing phase I/II, open-label, multicenter study enrolling patients with previously untreated PTCL. Phase I followed a standard 3+3 dose-escalation design, with oral Golidocitinib 150 mg every other day (QOD) as dose level 1 (DL1) and the target dose of 150 mg once daily (QD) as dose level 2 (DL2). Treatment consisted of CHOP alone in cycle 1, followed by Golidocitinib plus CHOP in cycles 2-6 (21 days each). After induction, patients could receive Golidocitinib maintenance for up to 2 years. Transplant-eligible patients could undergo autologous stem cell transplantation (ASCT) before maintenance. Tumor response was assessed by investigators according to the Lugano 2014 criteria. Treatment-emergent adverse events (TEAEs) were graded according to CTCAE v5.0. The data cutoff date was July 23, 2026.
Results
As of the data cutoff date, 31 patients had received treatment. Median age was 62 years (range, 39-77), and 16 patients (51.6%) were female. Histologic subtypes were angioimmunoblastic T-cell lymphoma in 22 patients (71.0%), PTCL not otherwise specified in 5 (16.1%), ALK-negative anaplastic large-cell lymphoma in 2 (6.5%), monomorphic epitheliotropic intestinal T-cell lymphoma in 1 (3.2%), and intestinal T-cell lymphoma in 1 (3.2%). Twenty-eight patients (90.3%) had stage III/IV disease. The first 3 patients received Golidocitinib 150 mg QOD at DL1, with no dose-limiting toxicities (DLTs) observed. DL2 was initiated at 150 mg QD. No DLTs were observed in the first 3 patients at DL2, and 150 mg QD was selected as the recommended phase 2 dose (RP2D). The remaining 25 patients received the RP2D. Among 22 efficacy-evaluable patients, 14 achieved complete response (CR), 5 achieved partial response, and 3 had progressive disease. The objective response rate was 86.4% (19/22), and the CR rate was 63.6% (14/22). Thirteen of 14 CRs (92.9%) were documented at the first response assessment. Median time from enrollment to data cutoff in the efficacy population was 6.6 months (range, 1.6-11.7). Duration of response, progression-free survival, and overall survival data remain immature. Safety was assessed in all 31 patients. The most common ≥ grade 3 TEAEs were white blood cell count decreased (12/31 [38.7%]), neutrophil count decreased (10/31 [32.3%]), and platelet count decreased (8/31 [25.8%]). Most hematologic TEAEs first occurred in cycle 1, when patients received CHOP alone. Cytomegalovirus (CMV) infection occurred in 15 patients (48.4%), with all during cycles 4-6. Most CMV infections were grade 1-2 (9/15), and 6 were grade 3. These events were manageable with standard clinical measures. No TEAE related deaths were reported.
Conclusions
Golidocitinib plus CHOP resulted in an objective response rate of 86.4% and a complete response rate of 63.6%, with most complete responses documented at the first assessment. The safety profile was manageable, with cytopenias occurring predominantly in cycle 1 and CMV infections in cycles 4-6. Longer follow-up is required to characterize response durability and survival.